Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Colorectal Neoplasms

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 90 articles:
HTML format



Single Articles


    January 2022
  1. TRAN TN, Peeters M, Hoeck S, Van Hal G, et al
    Optimizing the colorectal cancer screening programme using faecal immunochemical test (FIT) in Flanders, Belgium from the "interval cancer" perspective.
    Br J Cancer. 2022 Jan 12. pii: 10.1038/s41416-021-01694.
    PubMed     Abstract available


  2. YCHOU M, Rivoire M, Thezenas S, Guimbaud R, et al
    Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial.
    Br J Cancer. 2022 Jan 6. pii: 10.1038/s41416-021-01644.
    PubMed     Abstract available


    December 2021
  3. GUO S, Li J, Huang Z, Yue T, et al
    The CBS-H2S axis promotes liver metastasis of colon cancer by upregulating VEGF through AP-1 activation.
    Br J Cancer. 2021 Dec 24. pii: 10.1038/s41416-021-01681.
    PubMed     Abstract available


  4. ADIB E, El Zarif T, Nassar AH, Akl EW, et al
    CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer.
    Br J Cancer. 2021 Dec 23. pii: 10.1038/s41416-021-01673.
    PubMed     Abstract available


  5. ELEZ E, Gomez-Espana MA, Gravalos C, Garcia-Alfonso P, et al
    Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial.
    Br J Cancer. 2021 Dec 22. pii: 10.1038/s41416-021-01638.
    PubMed     Abstract available


  6. MCDOWELL R, Perrott S, Murchie P, Cardwell C, et al
    Oral antibiotic use and early-onset colorectal cancer: findings from a case-control study using a national clinical database.
    Br J Cancer. 2021 Dec 17. pii: 10.1038/s41416-021-01665.
    PubMed     Abstract available


  7. ZHANG X, Li X, He Y, Law PJ, et al
    Phenome-wide association study (PheWAS) of colorectal cancer risk SNP effects on health outcomes in UK Biobank.
    Br J Cancer. 2021 Dec 15. pii: 10.1038/s41416-021-01655.
    PubMed     Abstract available


  8. MATSUMOTO T, Okayama H, Nakajima S, Saito K, et al
    SH2D4A downregulation due to loss of chromosome 8p is associated with poor prognosis and low T cell infiltration in colorectal cancer.
    Br J Cancer. 2021 Dec 10. pii: 10.1038/s41416-021-01660.
    PubMed     Abstract available


    November 2021
  9. MANCA P, Corallo S, Lonardi S, Fuca G, et al
    Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study.
    Br J Cancer. 2021 Nov 22. pii: 10.1038/s41416-021-01591.
    PubMed     Abstract available


  10. DASH P, Ghatak S, Topi G, Satapathy SR, et al
    High PGD2 receptor 2 levels are associated with poor prognosis in colorectal cancer patients and induce VEGF expression in colon cancer cells and migration in a zebrafish xenograft model.
    Br J Cancer. 2021 Nov 8. pii: 10.1038/s41416-021-01595.
    PubMed     Abstract available


  11. MAJANO SB, Lyratzopoulos G, Rachet B, de Wit NJ, et al
    Do presenting symptoms, use of pre-diagnostic endoscopy and risk of emergency cancer diagnosis vary by comorbidity burden and type in patients with colorectal cancer?
    Br J Cancer. 2021 Nov 5. pii: 10.1038/s41416-021-01603.
    PubMed     Abstract available


    October 2021
  12. TAKEDA T, Yokoyama Y, Takahashi H, Okuzaki D, et al
    A stem cell marker KLF5 regulates CCAT1 via three-dimensional genome structure in colorectal cancer cells.
    Br J Cancer. 2021 Oct 27. pii: 10.1038/s41416-021-01579.
    PubMed     Abstract available


  13. OUAHOUD S, Jacobs RJ, Kodach LL, Voorneveld PW, et al
    Statin use is associated with a reduced incidence of colorectal cancer expressing SMAD4.
    Br J Cancer. 2021 Oct 26. pii: 10.1038/s41416-021-01604.
    PubMed     Abstract available


  14. OHSHIMA K, Oi R, Okuzaki D, Motooka D, et al
    Mitochondrial matrix protein C14orf159 attenuates colorectal cancer metastasis by suppressing Wnt/beta-catenin signalling.
    Br J Cancer. 2021 Oct 23. pii: 10.1038/s41416-021-01582.
    PubMed     Abstract available


  15. ARAI H, Xiao Y, Millstein J, Wang J, et al
    Germline polymorphisms in genes maintaining the replication fork predict the efficacy of oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
    Br J Cancer. 2021 Oct 23. pii: 10.1038/s41416-021-01592.
    PubMed     Abstract available


  16. AASEBO K, Bruun J, Bergsland CH, Nunes L, et al
    Prognostic role of tumour-infiltrating lymphocytes and macrophages in relation to MSI, CDX2 and BRAF status: a population-based study of metastatic colorectal cancer patients.
    Br J Cancer. 2021 Oct 20. pii: 10.1038/s41416-021-01586.
    PubMed     Abstract available


  17. KONUKIEWITZ B, Schmitt M, Silva M, Pohl J, et al
    Loss of CDX2 in colorectal cancer is associated with histopathologic subtypes and microsatellite instability but is prognostically inferior to hematoxylin-eosin-based morphologic parameters from the WHO classification.
    Br J Cancer. 2021 Oct 6. pii: 10.1038/s41416-021-01553.
    PubMed     Abstract available


    September 2021
  18. ZHANG J, Nyvang D, Ibsen DB, Olsen A, et al
    Adherence to the Danish food-based dietary guidelines and risk of colorectal cancer: a cohort study.
    Br J Cancer. 2021 Sep 30. pii: 10.1038/s41416-021-01556.
    PubMed     Abstract available


  19. BRETAGNE JF, Carlo A, Piette C, Rousseau C, et al
    Significant decrease in interval colorectal cancer incidence after implementing immunochemical testing in a multiple-round guaiac-based screening programme.
    Br J Cancer. 2021 Sep 12. pii: 10.1038/s41416-021-01546.
    PubMed     Abstract available


  20. CHEN D, Bao X, Zhang R, Ding Y, et al
    Depiction of the genomic and genetic landscape identifies CCL5 as a protective factor in colorectal neuroendocrine carcinoma.
    Br J Cancer. 2021;125:994-1002.
    PubMed     Abstract available


  21. LIU Z, Thong MSY, Doege D, Koch-Gallenkamp L, et al
    Prevalence of benefit finding and posttraumatic growth in long-term cancer survivors: results from a multi-regional population-based survey in Germany.
    Br J Cancer. 2021;125:877-883.
    PubMed     Abstract available


    July 2021
  22. ZABOROWSKI AM, Winter DC, Lynch L
    The therapeutic and prognostic implications of immunobiology in colorectal cancer: a review.
    Br J Cancer. 2021 Jul 23. pii: 10.1038/s41416-021-01475.
    PubMed     Abstract available


  23. FURTADO FS, Suarez-Weiss KE, Vangel M, Clark JW, et al
    Clinical impact of PET/MRI in oligometastatic colorectal cancer.
    Br J Cancer. 2021 Jul 19. pii: 10.1038/s41416-021-01494.
    PubMed     Abstract available


  24. ZOLTICK ES, Smith-Warner SA, Yuan C, Wang M, et al
    Sugar-sweetened beverage, artificially sweetened beverage and sugar intake and colorectal cancer survival.
    Br J Cancer. 2021 Jul 15. pii: 10.1038/s41416-021-01487.
    PubMed     Abstract available


  25. TEN HOORN S, Sommeijer DW, Elliott F, Fisher D, et al
    Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone.
    Br J Cancer. 2021 Jul 12. pii: 10.1038/s41416-021-01477.
    PubMed     Abstract available


  26. WANG X, Liu Q, Halfdanarson OO, Zoega H, et al
    Proton pump inhibitors and survival in patients with colorectal cancer: a Swedish population-based cohort study.
    Br J Cancer. 2021 Jul 12. pii: 10.1038/s41416-021-01480.
    PubMed     Abstract available


  27. MORETTO R, Rossini D, Conca V, Lonardi S, et al
    CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies.
    Br J Cancer. 2021 Jul 12. pii: 10.1038/s41416-021-01483.
    PubMed     Abstract available


  28. HUA X, Kratz M, Malen RC, Dai JY, et al
    Association between post-treatment circulating biomarkers of inflammation and survival among stage II-III colorectal cancer patients.
    Br J Cancer. 2021 Jul 6. pii: 10.1038/s41416-021-01458.
    PubMed     Abstract available


  29. MELTZER S, Torgunrud A, Abrahamsson H, Solbakken AM, et al
    The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer.
    Br J Cancer. 2021;125:240-246.
    PubMed     Abstract available


    June 2021
  30. LEE KH, Chen WS, Jiang JK, Yang SH, et al
    The efficacy of anti-EGFR therapy in treating metastatic colorectal cancer differs between the middle/low rectum and the left-sided colon.
    Br J Cancer. 2021 Jun 29. pii: 10.1038/s41416-021-01470.
    PubMed     Abstract available


  31. LIN M, Fang Y, Li Z, Li Y, et al
    S100P contributes to promoter demethylation and transcriptional activation of SLC2A5 to promote metastasis in colorectal cancer.
    Br J Cancer. 2021 Jun 29. pii: 10.1038/s41416-021-01306.
    PubMed     Abstract available


  32. GUO F, De Brabander I, Francart J, Candeur M, et al
    Correction: Benefits of switching from guaiac-based faecal occult blood to faecal immunochemical testing: experience from the Wallonia-Brussels colorectal cancer screening programme.
    Br J Cancer. 2021 Jun 28. pii: 10.1038/s41416-021-01468.
    PubMed    


  33. SEFRIOUI D, Beaussire L, Gillibert A, Blanchard F, et al
    CEA, CA19-9, circulating DNA and circulating tumour cell kinetics in patients treated for metastatic colorectal cancer (mCRC).
    Br J Cancer. 2021 Jun 10. pii: 10.1038/s41416-021-01431.
    PubMed     Abstract available


  34. DIXON SW, Collard TJ, Mortensson EMH, Legge DN, et al
    5-Aminosalicylic acid inhibits stem cell function in human adenoma-derived cells: implications for chemoprophylaxis in colorectal tumorigenesis.
    Br J Cancer. 2021;124:1959-1969.
    PubMed     Abstract available


    May 2021
  35. OUAHOUD S, Jacobs RJ, Peppelenbosch MP, Fuhler GM, et al
    Correction: Kinome-wide analysis of the effect of statins in colorectal cancer.
    Br J Cancer. 2021 May 10. pii: 10.1038/s41416-021-01426.
    PubMed    


  36. SALVIANTI F, Gelmini S, Mancini I, Pazzagli M, et al
    Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study.
    Br J Cancer. 2021 May 5. pii: 10.1038/s41416-021-01399.
    PubMed     Abstract available


  37. FRIEND T, Stebbing J
    Profiling circulating tumour cells and cell free DNA together in metastatic colon cancer.
    Br J Cancer. 2021 May 5. pii: 10.1038/s41416-021-01397.
    PubMed     Abstract available


  38. KANE AM, Liu C, Fennell LJ, McKeone DM, et al
    Aspirin reduces the incidence of metastasis in a pre-clinical study of Braf mutant serrated colorectal neoplasia.
    Br J Cancer. 2021;124:1820-1827.
    PubMed     Abstract available


  39. AMADOU A, Freisling H, Jenab M, Tsilidis KK, et al
    Prevalent diabetes and risk of total, colorectal, prostate and breast cancers in an ageing population: meta-analysis of individual participant data from cohorts of the CHANCES consortium.
    Br J Cancer. 2021;124:1882-1890.
    PubMed     Abstract available


    April 2021
  40. CHEN KH, Lin LI, Yuan CT, Tseng LH, et al
    Association between risk factors, molecular features and CpG island methylator phenotype colorectal cancer among different age groups in a Taiwanese cohort.
    Br J Cancer. 2021 Apr 12. pii: 10.1038/s41416-021-01300.
    PubMed     Abstract available


  41. LUND CM, Vistisen KK, Olsen AP, Bardal P, et al
    The effect of geriatric intervention in frail older patients receiving chemotherapy for colorectal cancer: a randomised trial (GERICO).
    Br J Cancer. 2021 Apr 7. pii: 10.1038/s41416-021-01367.
    PubMed     Abstract available


  42. KIM DW, Tan E, Zhou JM, Schell MJ, et al
    A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer.
    Br J Cancer. 2021 Apr 7. pii: 10.1038/s41416-021-01368.
    PubMed     Abstract available


  43. BAXTER MA, Murphy J, Cameron D, Jordan J, et al
    The impact of COVID-19 on systemic anticancer treatment delivery in Scotland.
    Br J Cancer. 2021;124:1353-1356.
    PubMed     Abstract available


  44. KREGTING LM, Kaljouw S, de Jonge L, Jansen EEL, et al
    Effects of cancer screening restart strategies after COVID-19 disruption.
    Br J Cancer. 2021;124:1516-1523.
    PubMed     Abstract available


  45. THOMSON A, Bento DFC, Scurr MJ, Smart K, et al
    Prognostic significance of interleukin-17A-producing colorectal tumour antigen-specific T cells.
    Br J Cancer. 2021;124:1552-1555.
    PubMed     Abstract available


    March 2021
  46. FEARON DT, Janowitz T
    AMD3100/Plerixafor overcomes immune inhibition by the CXCL12-KRT19 coating on pancreatic and colorectal cancer cells.
    Br J Cancer. 2021 Mar 26. pii: 10.1038/s41416-021-01315.
    PubMed     Abstract available


  47. GOLDER AM, McMillan DC, Park JH, Mansouri D, et al
    The prognostic value of combined measures of the systemic inflammatory response in patients with colon cancer: an analysis of 1700 patients.
    Br J Cancer. 2021 Mar 24. pii: 10.1038/s41416-021-01308.
    PubMed     Abstract available


  48. OUAHOUD S, Jacobs RJ, Peppelenbosch MP, Fuhler GM, et al
    Kinome-wide analysis of the effect of statins in colorectal cancer.
    Br J Cancer. 2021 Mar 19. pii: 10.1038/s41416-021-01318.
    PubMed     Abstract available


  49. ROSENDAHL HUBER A, Pleguezuelos-Manzano C, Puschhof J
    A bacterial mutational footprint in colorectal cancer genomes.
    Br J Cancer. 2021 Mar 19. pii: 10.1038/s41416-021-01273.
    PubMed     Abstract available


  50. ARTHUR RS, Dannenberg AJ, Kim M, Rohan TE, et al
    The association of body fat composition with risk of breast, endometrial, ovarian and colorectal cancers among normal weight participants in the UK Biobank.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-020-01210.
    PubMed     Abstract available


  51. YAEGASHI M, Iwaya T, Sasaki N, Fujita M, et al
    Frequent post-operative monitoring of colorectal cancer using individualised ctDNA validated by multiregional molecular profiling.
    Br J Cancer. 2021 Mar 3. pii: 10.1038/s41416-021-01266.
    PubMed     Abstract available


  52. NIMPTSCH K, Lee DH, Zhang X, Song M, et al
    Dairy intake during adolescence and risk of colorectal adenoma later in life.
    Br J Cancer. 2021;124:1160-1168.
    PubMed     Abstract available


    February 2021
  53. SHANG Y, Zhang X, Lu L, Jiang K, et al
    Pharmaceutical immunoglobulin G impairs anti-carcinoma activity of oxaliplatin in colon cancer cells.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01272.
    PubMed     Abstract available


  54. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
    Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
    PubMed     Abstract available


  55. PINTO-FERNANDEZ A, Salio M, Partridge T, Chen J, et al
    Deletion of the deISGylating enzyme USP18 enhances tumour cell antigenicity and radiosensitivity.
    Br J Cancer. 2021;124:817-830.
    PubMed     Abstract available


    January 2021
  56. ZHANG X, Theodoratou E, Li X, Farrington SM, et al
    Genetically predicted physical activity levels are associated with lower colorectal cancer risk: a Mendelian randomisation study.
    Br J Cancer. 2021 Jan 29. pii: 10.1038/s41416-020-01236.
    PubMed     Abstract available


  57. BAILEY SER, Abel GA, Atkins A, Byford R, et al
    Diagnostic performance of a faecal immunochemical test for patients with low-risk symptoms of colorectal cancer in primary care: an evaluation in the South West of England.
    Br J Cancer. 2021 Jan 19. pii: 10.1038/s41416-020-01221.
    PubMed     Abstract available


  58. UENO H, Ishiguro M, Nakatani E, Ishikawa T, et al
    Prognostic value of desmoplastic reaction characterisation in stage II colon cancer: prospective validation in a Phase 3 study (SACURA Trial).
    Br J Cancer. 2021 Jan 7. pii: 10.1038/s41416-020-01222.
    PubMed     Abstract available


  59. CULLIFORD R, Cornish AJ, Law PJ, Farrington SM, et al
    Lack of an association between gallstone disease and bilirubin levels with risk of colorectal cancer: a Mendelian randomisation analysis.
    Br J Cancer. 2021 Jan 7. pii: 10.1038/s41416-020-01211.
    PubMed     Abstract available


  60. BRAGAGNOLI AC, Araujo RLC, Ferraz MW, Dos Santos LV, et al
    Metformin plus lrinotecan in patients with refractory colorectal cancer: a phase 2 clinical trial.
    Br J Cancer. 2021 Jan 4. pii: 10.1038/s41416-020-01208.
    PubMed     Abstract available


    December 2020
  61. LOUGHREY MB, Fisher NC, McCooey AJ, Dunne PD, et al
    Comment on "Identification of EMT-related high-risk stage II colorectal cancer and characterisation of metastasis-related genes".
    Br J Cancer. 2020 Dec 14. pii: 10.1038/s41416-020-01213.
    PubMed    


  62. YASUI K, Shida D, Nakamura Y, Ahiko Y, et al
    Postoperative, but not preoperative, inflammation-based prognostic markers are prognostic factors in stage III colorectal cancer patients.
    Br J Cancer. 2020 Dec 1. pii: 10.1038/s41416-020-01189.
    PubMed     Abstract available


  63. ZELLWEGER M, Gonzalez M
    Comment on: the myth of pulmonary metastasectomy.
    Br J Cancer. 2020;123:1833-1834.
    PubMed    


  64. MACBETH F, Fallowfield DL
    Reply to 'Comment on "The myth of pulmonary metastasectomy'".
    Br J Cancer. 2020;123:1835-1836.
    PubMed    


    November 2020
  65. YU J, Li S, Xu Z, Guo J, et al
    CDX2 inhibits epithelial-mesenchymal transition in colorectal cancer by modulation of Snail expression and beta-catenin stabilisation via transactivation of PTEN expression.
    Br J Cancer. 2020 Nov 26. pii: 10.1038/s41416-020-01148.
    PubMed     Abstract available


  66. ALEXANDER PG, Roseweir AK, Pennel KAF, van Wyk HC, et al
    The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer.
    Br J Cancer. 2020 Nov 23. pii: 10.1038/s41416-020-01168.
    PubMed     Abstract available


  67. JACOME AA, Vreeland TJ, Johnson B, Kawaguchi Y, et al
    The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients.
    Br J Cancer. 2020 Nov 19. pii: 10.1038/s41416-020-01169.
    PubMed     Abstract available


  68. HUIJBERTS SCFA, Boelens MC, Bernards R, Opdam FL, et al
    Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib.
    Br J Cancer. 2020 Nov 18. pii: 10.1038/s41416-020-01147.
    PubMed     Abstract available


  69. HEINEMANN V, von Weikersthal LF, Decker T, Kiani A, et al
    FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
    Br J Cancer. 2020 Nov 6. pii: 10.1038/s41416-020-01140.
    PubMed     Abstract available


  70. FANG Z, He M, Song M
    Serum lipid profiles and risk of colorectal cancer: a prospective cohort study in the UK Biobank.
    Br J Cancer. 2020 Nov 3. pii: 10.1038/s41416-020-01143.
    PubMed     Abstract available


  71. LI YY, Gao LJ, Zhang YX, Liu SJ, et al
    Bisphosphonates and risk of cancers: a systematic review and meta-analysis.
    Br J Cancer. 2020;123:1570-1581.
    PubMed     Abstract available


    October 2020
  72. CHA PH, Hwang JH, Kwak DK, Koh E, et al
    APC loss induces Warburg effect via increased PKM2 transcription in colorectal cancer.
    Br J Cancer. 2020 Oct 19. pii: 10.1038/s41416-020-01118.
    PubMed     Abstract available


  73. WENSINK GE, Elferink MAG, May AM, Mol L, et al
    Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era.
    Br J Cancer. 2020 Oct 13. pii: 10.1038/s41416-020-01076.
    PubMed     Abstract available


  74. ROSSINI D, Lonardi S, Antoniotti C, Santini D, et al
    Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
    Br J Cancer. 2020 Oct 7. pii: 10.1038/s41416-020-01089.
    PubMed     Abstract available


  75. HE F, Ju HQ, Ding Y, Jiang Z, et al
    Association between adjuvant chemotherapy and survival in patients with rectal cancer and pathological complete response after neoadjuvant chemoradiotherapy and resection.
    Br J Cancer. 2020;123:1244-1252.
    PubMed     Abstract available


    September 2020
  76. SIMIN J, Fornes R, Liu Q, Olsen RS, et al
    Antibiotic use and risk of colorectal cancer: a systematic review and dose-response meta-analysis.
    Br J Cancer. 2020 Sep 24. pii: 10.1038/s41416-020-01082.
    PubMed     Abstract available


  77. PAPE J, Magdeldin T, Stamati K, Nyga A, et al
    Cancer-associated fibroblasts mediate cancer progression and remodel the tumouroid stroma.
    Br J Cancer. 2020;123:1178-1190.
    PubMed     Abstract available


  78. MURAHASHI S, Akiyoshi T, Sano T, Fukunaga Y, et al
    Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence.
    Br J Cancer. 2020;123:803-810.
    PubMed     Abstract available


    August 2020
  79. MACBETH F, Fallowfield L
    The myth of pulmonary metastasectomy.
    Br J Cancer. 2020;123:499-500.
    PubMed     Abstract available


    July 2020
  80. HOPPENER DJ, Nierop PMH, Hof J, Sideras K, et al
    Enrichment of the tumour immune microenvironment in patients with desmoplastic colorectal liver metastasis.
    Br J Cancer. 2020;123:196-206.
    PubMed     Abstract available


    June 2020
  81. ROOS VH, Kallenberg FGJ, van der Vlugt M, Bongers EJC, et al
    Addition of an online, validated family history questionnaire to the Dutch FIT-based screening programme did not improve its diagnostic yield.
    Br J Cancer. 2020;122:1865-1871.
    PubMed     Abstract available


    May 2020
  82. STREMITZER S, Vermeulen P, Graver S, Kockx M, et al
    Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases.
    Br J Cancer. 2020;122:1518-1524.
    PubMed     Abstract available


  83. QIN B, Zou S, Li K, Wang H, et al
    CSN6-TRIM21 axis instigates cancer stemness during tumorigenesis.
    Br J Cancer. 2020;122:1673-1685.
    PubMed     Abstract available


    April 2020
  84. DAI W, Wang G, Chwa J, Oh ME, et al
    Mitochondrial division inhibitor (mdivi-1) decreases oxidative metabolism in cancer.
    Br J Cancer. 2020;122:1288-1297.
    PubMed     Abstract available


  85. VAN GEEL RMJM, van Brummelen EMJ, Eskens FALM, Huijberts SCFA, et al
    Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.
    Br J Cancer. 2020;122:1166-1174.
    PubMed     Abstract available


    March 2020
  86. OTANDAULT A, Abraham JD, Al Amir Dache Z, Khalyfa A, et al
    Hypoxia differently modulates the release of mitochondrial and nuclear DNA.
    Br J Cancer. 2020;122:715-725.
    PubMed     Abstract available


  87. HERIOT AG
    Whither Anal Cancer?
    Br J Cancer. 2020;122:733-734.
    PubMed     Abstract available


  88. SEKHAR H, Malcomson L, Kochhar R, Sperrin M, et al
    Temporal improvements in loco-regional failure and survival in patients with anal cancer treated with chemo-radiotherapy: treatment cohort study (1990-2014).
    Br J Cancer. 2020;122:749-758.
    PubMed     Abstract available


  89. APARICIO T, Bennouna J, Le Malicot K, Boige V, et al
    Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial.
    Br J Cancer. 2020;122:957-962.
    PubMed     Abstract available


    February 2020
  90. VAN DE BEEK I, Glykofridis IE, Wolthuis RMF, Gille HJJP, et al
    No evidence for increased prevalence of colorectal carcinoma in 399 Dutch patients with Birt-Hogg-Dube syndrome.
    Br J Cancer. 2020;122:590-594.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: